Smith & Nephew (SNN) Stock: Buy, Sell, or Hold?
SNN - Smith & Nephew plc
$27.50
-0.12 (-0.43%)
▼
5d:
-4.15%
30d:
-7.84%
90d:
-10.34%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When SNN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SNN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SNN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$50.44
Based on 6.2% avg growth
INTRINSIC VALUE TODAY
$31.32
12.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNN is currently trading at $27.50, which is considered oversold relative to its 30-day fair value range of $28.38 to $30.29. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.4) compared to its historical average (15.5). Remarkably, the market is currently pricing in an annual earnings decline of 9.6% over the next few years. This pessimistic expectation contrasts with the company's recent 5.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SNN is in a downtrend. The price is currently testing key support at $27.23. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNN scores 18/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $32.86 (+19.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNN is in a downtrend. The price is currently testing key support at $27.23. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNN scores 18/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $32.86 (+19.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$28.38 -
$30.29
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
54.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (18/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($32.86)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$28.38 -
$30.29
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$27.23
Resistance Level
$29.69
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.41
Wall Street Target
$32.86
(+19.5%)
Revenue Growth (YoY)
4.6%
Earnings Growth (YoY)
5.7%
Profit Margin
10.1%
Valuation Discount vs History
-9.6% cheaper
PE vs Historical
11.4 vs 15.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-9.6%
(market-implied from PE analysis)
1-Year Target
$24.86
(-10%)
2-Year Target
$22.47
(-18%)
3-Year Target
$20.32
(-26%)
3-Yr Target (if PE normalizes)
(PE: 11→16)
$27.60
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 8.4%)
$61.90
(+125%)
Base:
(SPY PE: 11.4, Growth: 8.4%)
$35.02
(+27%)
Bear:
(PE: 9.7, Growth: 8.4%)
$29.76
(+8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 18.92 | Current EPS (TTM): $1.46
Bull Case
$50.16
(+82%)
Analyst growth 65.1%, PE expands to 20.8
Base Case
$45.60
(+66%)
Market implied 65.1%, PE stable at 18.9
Bear Case
$18.78
(-32%)
Severe decline -20.0%, PE contracts to 16.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.4 to 15.5
Stabilization Target:
$37.36
(+35.9%)
PE Expansion Potential:
+35.9%
Share & Embed Analysis
Last updated: September 13, 2026 8:21 AM ET
Data refreshes hourly during market hours. Next update: 9:21 AM
Data refreshes hourly during market hours. Next update: 9:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 40 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 41 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 41 HOLD |
